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Thanks to advances in genetic testing, there is now a way for consumers to test for
the greatest genetic risk factor for late-onset Alzheimer’s disease.
Alzheimer’s disease is a progressive and fatal neurodegenerative disorder that
primarily affects older adults. It is the most common cause of dementia. It is the third
leading cause of death, behind heart disease and cancer. An estimated 700,000
Americans 65 and older will have Alzheimer’s when they die. In a recent study asking
Americans age 50 or older the condition they were most afraid of, the number one
fear was Alzheimer’s, with 39 percent; followed by cancer, at 30 percent.
Genetic testing is available to people who want to know if they carry a variant of a gene that confers susceptibility for Alzheimer’s. But knowing
whether to get tested is hard. Billion Photos/Shutterstock.com
Clinically, patients with Alzheimer’s most commonly present with insidiously progressive memory
loss, difficulty thinking and understanding and mental confusion.
As a scientist who has been involved in Alzheimer’s research for the past 18 years, I think genetic
testing represents a significant advance in being able to assess one’s risk for this disease. But people
should be aware that there are several things to consider before testing for this treacherous disease at
home.
Why is ApoE important for Alzheimer’s risk?
The vast majority of Alzheimer’s cases have late onset, or after age 65, and advancing age is the
greatest risk factor. Alzheimer’s affects one in 10 people over the age of 65, and almost two-thirds of
Americans with Alzheimer’s are women.
In addition to advancing age, there are known genetic risk factors associated with Alzheimer’s, with a
gene called ApoE4 being the most important of all of them. The ApoE gene provides instructions for
making a protein called apolipoprotein E. This protein combines with fats, or lipids, in the brain to
form molecules called lipoproteins. Lipoproteins are responsible for packaging cholesterol and other
fats and ferrying them around in the brain. Scientists have long known that ApoE4 is related to a
buildup of amyloid in the brain, one of the hallmarks of Alzheimer’s. But a recent study suggested that
ApoE4 also contributes to the buildup of tau, a second protein that has long been implicated in the
development of Alzheimer’s. Thus, the question of ApoE4 testing becomes even more urgent for
many.
The ApoE gene has three different alleles, or variations of a gene that can occur by mutation: ApoE2,
ApoE3 and ApoE4. These alleles occur at the same location as the gene.
Everyone has two copies of this gene, and the combination of alleles determines your ApoE
“genotype” – E2/E2, E2/E3, E2/E4, E3/E3, E3/E4 or E4/E4. The E2 allele is the rarest form of ApoE,
but it’s a good one to have. Carrying even one copy appears to reduce the risk of developing
Alzheimer’s by up to 40 percent.
The ApoE3 is the most common allele and doesn’t seem to influence risk. The ApoE4 allele is less
common than E3, present in about 10 to 15 percent of people, but it confers a significant risk for AD.
Having one copy of E4 (E3/E4) can double or triple your risk, while two copies of (E4/E4) can
increase the risk by 10-15 times. It is noteworthy that 65-80 percent of all Alzheimer’s patients have at
least one APOE4 allele.
This allele also lowers the age of onset.
Risk of susceptibility, based on alleles. Alzheimers.org, CC BY-SA
Testing for ApoE4
Testing has become incredibly easy and fast through 23andMe, the personal genetics company that 
won approval from the FDA in April 2017 to market genetic testing directly to consumers. In its late-
onset Alzheimer’s report, 23andMe provides people with their ApoE gene status, following the
mailing of a saliva sample to the company.
But a much more difficult question is: Should I be tested? There are important implications of
learning one’s ApoE4 genetic status, and consumers should consider these before they decide to be
tested. Indeed, most professional medical organizations, including the National Institutes of Health,
recommend genetic testing of ApoE4 status only for people volunteering for clinical trials.
A woman and her doctor discuss healthy aging. Dennis Sabo/Shutterstock.com
Pros of testing may include:
It is currently known from prevention research that people with the APOE4 gene can take a
number of lifestyle steps to mitigate their risk.
Being able to participate in clinical trials.
APOE4 also has some predictive value for cardiovascular risk.
Cons of testing may include:
Stress on family.
Emotional distress.
Financial implications in terms of insurance or long-term care options.
Effect on employment.
The effect of knowing your status
One of the major drawbacks to being tested for the ApoE4 gene is that the test is considered what is
called a susceptibility test because it has limited predictive value. Having the E4 allele does not mean
that a person will be diagnosed with Alzheimer’s. Many E4 carriers may live long lives without ever
developing the disease, and many noncarriers still have risk for Alzheimer’s. This is critically
important to understand before having genetic testing for ApoE4.
Several studies have now examined the impact of ApoE4 testing on individuals. The NIH REVEAL-
SCAN project examined the effect of learning ApoE4 status in those who were not showing any
symptoms of dementia but had first-degree relatives affected by Alzheimer’s. The data indicated that
knowing one’s ApoE status caused only mild and brief psychological problems in those found to have
inherited E4 alleles.
In a more recent study, adverse psychological reactions were reported by a fraction of the
participants, including those who had specifically sought testing. However, nearly all of those
interviewed said that they had benefited in the long term from lifestyle changes they subsequently 
made.
Consideration of other risk factors
Harboring the ApoE4 allele is the most important genetic risk factor for late-onset Alzheimer’s, and
knowing one’s E4 allele status certainly could be transforming, particularly in terms of preventative,
beneficial lifestyle changes individuals may undergo.
However, there are important considerations to take into account before testing to help mitigate
stress and anxiety associated with a positive E4 test. Other experts and I suggest that people start by
becoming well-informed about the basics of ApoE4. If testing is carried out and a higher risk is
revealed, it is critically important those individuals obtain genetic counseling and be actively assisted
about how to proceed.
Whether you carry the ApoE4 gene or not, many other risk factors are thought to contribute to
Alzheimer’s, not just genes and old age. What you eat, how much you exercise, formal education,
smoking, how mentally active you remain and other factors have all been implicated.
Ultimately, the choice of whether to get a genetic test remains a personal one – all the more reason it’s
important to be informed about the pros and cons of Alzheimer’s screening and what doctors know
about your risk for the disease and whether viable treatment options are available.
 Dementia Genetic testing 23andMe Alzheimer's disease 
